Health and economic consequences of HCV lookback

Transfusion

Volumn 41, Issue 6, 2001, Pages 832-839

  Pereira, Arturo ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE EXPECTANCY; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PREDICTION; QUALITY OF LIFE; SCHOOL CHILD; SYSTEM ANALYSIS;

BLOOD TRANSFUSION; COSTS AND COST ANALYSIS; HEPACIVIRUS; HEPATITIS C; HUMANS; MARKOV CHAINS; MONTE CARLO METHOD;

EID: 0034965032     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41060832.x     Document Type: Article

References (35)

1. Recommendations for prevention and control of hepatitis C (HCV) infection and HCV-related chronic disease
2. Hepatitis C lookback
3. Transfusion-acquired hepatitis C: The Danish lookback experience
4. Completed hepatitis C lookback in Northern Ireland
5. Targeted hepatitis C lookback: Quebec, Canada
6. Evaluation of the effectiveness of targeted lookback for HCV infection in the United States - Interim results
7. Paving with good intentions: Learning from HCV lookback
8. Public health, public trust, and public decision making: Making hepatitis C virus lookback work
9. Collection and transfusion of blood in the United States, 1982-1988
10. Collection and transfusion of blood in the United States, 1989
11. Collection and transfusion of blood in the United States, 1992
12. A model of the health and economic impact of posttransfusion hepatitis C: Application to cost-effectiveness analysis of further expansion of HCV screening protocols
13. Long-term survival after blood transfusion
14. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life
15. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis
16. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy
17. Impaired health-related quality of life in chronic hepatitis C: The how, but not the why
18. Transmission of hepatitis C virus by transfusion in Orebro County, Sweden, 1990-1992
19. Functional limitations and disability among elders in the Framingham study
20. To C or not to C: These are the questions
21. Hepatitis C
22. Hepatitis C and alcohol
23. National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C
24. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
25. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia
26. Prevalence and clinical outcome of chronic hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening
27. Hepatitis C infection among survivors of childhood cancer
28. Recovery, persistence, and sequelae of hepatitis C virus infection: A perspective on long-term outcome
29. An evaluation of the process and cost associated with targeted lookbacks for HCV and general notification of transfused patients
30. Non-A, non-B posttransfusion hepatitis. Looking back in the second decade
31. Long course and prognostic factors of virus-induced cirrhosis of the liver
32. Long-term outcome of hepatitis C infection after liver transplantation
33. Estimates on the cost-effectiveness of a single course of interferon-a2b in patients with histologically mild chronic hepatitis
34. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis